Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CYRX 
Cryoport Inc (CYRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: CYRX (1-star) is a SELL. SELL since 3 days. Simulated Profits (-9.42%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.22
1 Year Target Price $13.22
| 4 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.41% | Avg. Invested days 23 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 417.06M USD | Price to earnings Ratio - | 1Y Target Price 13.22 |
Price to earnings Ratio - | 1Y Target Price 13.22 | ||
Volume (30-day avg) 10 | Beta 1.52 | 52 Weeks Range 4.58 - 11.44 | Updated Date 11/6/2025 |
52 Weeks Range 4.58 - 11.44 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.24 | Actual -0.18 |
Profitability
Profit Margin 29.23% | Operating Margin (TTM) -22.45% |
Management Effectiveness
Return on Assets (TTM) -4.05% | Return on Equity (TTM) -11.3% |
Valuation
Trailing PE - | Forward PE 58.14 | Enterprise Value 309449820 | Price to Sales(TTM) 1.71 |
Enterprise Value 309449820 | Price to Sales(TTM) 1.71 | ||
Enterprise Value to Revenue 1.3 | Enterprise Value to EBITDA -13 | Shares Outstanding 50066968 | Shares Floating 40922770 |
Shares Outstanding 50066968 | Shares Floating 40922770 | ||
Percent Insiders 3.87 | Percent Institutions 97.95 |
Upturn AI SWOT
Cryoport Inc
Company Overview
History and Background
Cryoport, Inc. was founded in 1999. It specializes in temperature-controlled supply chain solutions, primarily for the life sciences industry. The company has grown through acquisitions and partnerships, expanding its services globally.
Core Business Areas
- Cryopreservation Logistics: This segment provides temperature-controlled logistics solutions, including packaging, shipping, and monitoring, for cryogenic materials used in the life sciences industry.
- Cryopreservation Systems: This segment designs, manufactures, and markets specialized cryogenic freezers and related equipment for cell and gene therapies, regenerative medicine, and other applications.
- Cryopreservation Services: This segment provides cryogenic biostorage and related services to biopharmaceutical companies, academic institutions, and other research organizations.
Leadership and Structure
The leadership team consists of Jerrell Shelton (CEO), Mark Sawicki (Chief Commercial Officer), and Robert Stefanovich (CFO). The company has a board of directors responsible for overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Cryoport Express Shippers: These are specialized shipping containers designed to maintain cryogenic temperatures during transport. Market share is estimated at 35% in the cell and gene therapy logistics sector. Competitors include World Courier (owned by AmerisourceBergen), Marken (owned by UPS), and BioLife Solutions (BLFS).
- Cryoport Elite Services: Complete end-to-end temperature-controlled supply chain solutions. Competitors include World Courier and Marken. Revenue data is not publicly available in that level of detail.
- CryoStor Cell Freeze Media: Formulations designed to improve cell viability during cryopreservation, acquired through acquisition of BioLife Solutions assets. Competitors include STEMCELL Technologies, Corning and Sigma Aldrich. Revenue data is not publicly available in that level of detail.
Market Dynamics
Industry Overview
The temperature-controlled supply chain market for life sciences is growing rapidly due to the increasing demand for cell and gene therapies, biologics, and other temperature-sensitive products. The regulatory landscape is also becoming more stringent, requiring specialized logistics solutions.
Positioning
Cryoport is a leading player in the temperature-controlled supply chain for the life sciences, particularly in the cell and gene therapy space. Its competitive advantage lies in its specialized expertise, proprietary technology, and global network.
Total Addressable Market (TAM)
The global market for temperature-controlled pharmaceutical logistics is expected to reach $20 billion to $30 billion. Cryoport is well-positioned to capture a significant share of this market, focusing on the high-value segment of cell and gene therapies which is estimated to grow to $55 Billion by 2030.
Upturn SWOT Analysis
Strengths
- Specialized expertise in cryogenic logistics
- Proprietary technology and equipment
- Global network and infrastructure
- Strong relationships with leading biopharmaceutical companies
- High regulatory compliance standards
Weaknesses
- High operating costs
- Reliance on a few key customers
- Exposure to currency fluctuations
- Dependence on air transportation
Opportunities
- Growing demand for cell and gene therapies
- Expanding into new geographic markets
- Developing new product and service offerings
- Acquiring complementary businesses
- Increasing adoption of digital technologies
Threats
- Intense competition
- Technological obsolescence
- Regulatory changes
- Economic downturns
- Disruptions in the supply chain
Competitors and Market Share
Key Competitors
- UPS (UPS)
- AmerisourceBergen (ABC)
- BioLife Solutions (BLFS)
Competitive Landscape
Cryoport competes primarily on its specialized expertise, proprietary technology, and global network. It has a strong position in the cell and gene therapy logistics market, but faces competition from larger, more diversified logistics providers.
Major Acquisitions
MVE Biological Solutions
- Year: 2020
- Acquisition Price (USD millions): 320
- Strategic Rationale: Expanded Cryoport's cryogenic freezer portfolio and manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Cryoport has experienced rapid growth in recent years, driven by the increasing demand for its temperature-controlled logistics solutions. This growth has been fueled both organically and through strategic acquisitions.
Future Projections: Analyst estimates project continued growth for Cryoport, driven by the expansion of the cell and gene therapy market. Projections suggest annual revenue growth of 20-30% over the next few years.
Recent Initiatives: Recent initiatives include expanding its global network, investing in new technologies, and forming strategic partnerships.
Summary
Cryoport is a leading player in the temperature-controlled supply chain for the life sciences, particularly in the cell and gene therapy sector. The company's specialized expertise, proprietary technology, and global network provide a competitive advantage. High operating costs and reliance on key customers are potential risks. Opportunities exist in expanding into new markets and developing new products, but competition and regulatory changes pose threats.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cryoport Inc
Exchange NASDAQ | Headquaters Brentwood, TN, United States | ||
IPO Launch date 2005-03-15 | Chairman, President & CEO Mr. Jerrell W. Shelton | ||
Sector Industrials | Industry Integrated Freight & Logistics | Full time employees 1090 | Website https://www.cryoportinc.com |
Full time employees 1090 | Website https://www.cryoportinc.com | ||
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.